Price control could cut medicine development by 88% in California

Researchers from Biocom California and the California Life Sciences Association (CLSA) have released data analysing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline.

The analysis shows that implementing foreign reference pricing in Medicare Part D will negatively impact California’s biopharmaceutical sector and the R&D which thousands of companies use to develop new treatments and cures for patients internationally. The study was conducted by Vital Transformation, an international health economics firm, to examine the impact of Medicare Part B and D foreign reference pricing as proposed in H.R. 3, the Lower Drug Costs Now Act of 2019.

“International reference pricing proposals would tie US prices for medicines to prices in countries with different health systems and restricted availability and access to innovative medicines,” said Mike Guerra, President and CEO of CLSA.

“California’s innovation ecosystem, which leads the country in the development of innovative therapies, would be destroyed as a result. Reference pricing proposals would annihilate decades of progress and take our country backwards, and along with it the patients and families who are desperately looking for ground-breaking medicines.”

“These new data unequivocally show that importing foreign price controls into Medicare will slash investments in research and development, dramatically reduce the pipeline of new cures and treatments, and ultimately hurt the very patients who are most vulnerable to both chronic and life-threatening diseases,” said Joe Panetta, President and CEO of Biocom California. “It would be devastating for small California companies, which rely on capital investment to bring products to market. On behalf of California’s innovators, we urge Congress and the Administration to consider policies that would lower out-of-pocket costs for patients while continuing to foster an environment that supports innovation.”

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free